The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
His resignation would be effective from March 18, 2024
Development services for gene and cell therapies is planned to begin first in 2025
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Subscribe To Our Newsletter & Stay Updated
